
pmid: 17196881
Drug eluting stents (DES) are rapidly replacing intravascular brachytherapy for the treatment of bare metal in-stent restenosis (ISR). To date, there are no long-term follow up data supporting this practise. We report symptomatic repeat in-stent restenosis occurring 27 months after sirolimus eluting stent deployment for de novo in-stent restenosis. This case suggests that in a subgroup of patients with ISR, as with brachytherapy, the drug eluting stent may be simply delaying rather than inhibiting the restenotic process.
Male, Reoperation, Sirolimus, Time Factors, Middle Aged, Coronary Angiography, Prosthesis Failure, Coronary Restenosis, Blood Vessel Prosthesis Implantation, Coated Materials, Biocompatible, Humans, Stents, Immunosuppressive Agents, Follow-Up Studies
Male, Reoperation, Sirolimus, Time Factors, Middle Aged, Coronary Angiography, Prosthesis Failure, Coronary Restenosis, Blood Vessel Prosthesis Implantation, Coated Materials, Biocompatible, Humans, Stents, Immunosuppressive Agents, Follow-Up Studies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
